{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:06:39Z","timestamp":1777878399903,"version":"3.51.4"},"reference-count":86,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Chronic Disease"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:p>Proliferative retinopathies, such as neovascular age\u2013related macular degeneration and proliferative diabetic retinopathy, are a special health issue due to their contribution to irreversible blindness. Although the promoting conditions and physiopathology of proliferative retinopathies are different, these feature a highly detrimental angiogenesis driven by the overproduction of vascular endothelial growth factor (VEGF). This article describes the mechanism of action of ocular antiangiogenic therapies currently found in clinical development. Systems classify accordingly as (a) novel anti-VEGF systems, (b) molecules targeting non-VEGF pathways, and (c) gene therapies. Whereas most therapies are designed to neutralize VEGF, there is a significant set of products with diverse complexity and mechanism of action. Anti-VEGF therapies are still the most studied approach to tackle angiogenesis. Therapies targeting non-VEGF pathways, however, are highlighted because they could be an option for patients nonresponsive to anti-VEGF therapies. Finally, gene therapy is a promissory technology platform but still is subject to demonstrate safety and efficacy.<\/jats:p>","DOI":"10.1177\/20406223221140395","type":"journal-article","created":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T06:11:56Z","timestamp":1669961516000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Novel therapies for proliferative retinopathies"],"prefix":"10.1177","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2438-5465","authenticated-orcid":false,"given":"Juan Manuel","family":"Martinez-Alejo","sequence":"first","affiliation":[{"name":"Centro de Investigaci\u00f3n Sophia, Laboratorios Sophia SA de CV, Zapopan, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leopoldo Martin","family":"Baiza-Duran","sequence":"additional","affiliation":[{"name":"Laboratorios Sophia SA de CV, Zapopan, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5660-4431","authenticated-orcid":false,"given":"Juan de Dios","family":"Quintana-Hau","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Sophia, Laboratorios Sophia SA de CV, Paseo del Valle 4896, Technology Park, 45010 Zapopan, Jalisco, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,12,2]]},"reference":[{"key":"bibr1-20406223221140395","unstructured":"World Health Organization. Vision impairment and blindness. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/blindness-and-visual-impairment (2022, accessed 30 March 2022)"},{"key":"bibr2-20406223221140395","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2019-314422"},{"key":"bibr3-20406223221140395","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.93751"},{"key":"bibr4-20406223221140395","volume":"9","author":"GBD 2019 Blindness and Vision Impairment Collaborators and Vision Loss Expert Group of the Global Burden of Disease Study","year":"2021","journal-title":"Lancet Glob Health"},{"key":"bibr5-20406223221140395","doi-asserted-by":"publisher","DOI":"10.2147\/CIA.S143508"},{"key":"bibr6-20406223221140395","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S275968"},{"key":"bibr7-20406223221140395","first-page":"574","volume":"145","author":"Miller JW","year":"1994","journal-title":"Am J Pathol"},{"key":"bibr8-20406223221140395","doi-asserted-by":"publisher","DOI":"10.1096\/fj.09-145102"},{"key":"bibr9-20406223221140395","doi-asserted-by":"publisher","DOI":"10.1042\/CS20160129"},{"key":"bibr10-20406223221140395","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2019.10.008"},{"key":"bibr11-20406223221140395","doi-asserted-by":"publisher","DOI":"10.31377\/ammr.v2i1.634"},{"key":"bibr12-20406223221140395","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19041264"},{"key":"bibr13-20406223221140395","doi-asserted-by":"publisher","DOI":"10.1016\/j.pdpdt.2018.05.002"},{"key":"bibr14-20406223221140395","doi-asserted-by":"publisher","DOI":"10.3928\/23258160-20170329-03"},{"key":"bibr15-20406223221140395","doi-asserted-by":"publisher","DOI":"10.1016\/j.jphs.2018.11.001"},{"key":"bibr16-20406223221140395","first-page":"263","volume":"1","author":"Vinores SA.","year":"2006","journal-title":"Int J Nanomedicine"},{"key":"bibr17-20406223221140395","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2012.06.006"},{"key":"bibr18-20406223221140395","doi-asserted-by":"publisher","DOI":"10.7150\/thno\/v01p0395"},{"key":"bibr19-20406223221140395","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2011-300654"},{"key":"bibr20-20406223221140395","doi-asserted-by":"publisher","DOI":"10.18240\/ijo.2019.09.17"},{"key":"bibr21-20406223221140395","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.12.031"},{"key":"bibr22-20406223221140395","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2014.06.043"},{"key":"bibr23-20406223221140395","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics10030083"},{"key":"bibr24-20406223221140395","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-020-00235-y"},{"key":"bibr25-20406223221140395","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2013.107"},{"key":"bibr26-20406223221140395","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2014-305252"},{"key":"bibr27-20406223221140395","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.04.017"},{"key":"bibr28-20406223221140395","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S325763"},{"key":"bibr29-20406223221140395","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-011-0154-3"},{"key":"bibr30-20406223221140395","doi-asserted-by":"publisher","DOI":"10.4062\/biomolther.2013.113"},{"key":"bibr31-20406223221140395","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00018-6"},{"key":"bibr32-20406223221140395","unstructured":"Opthea Limited. OPT-302 with aflibercept in neovascular age-related macular degeneration (nAMD) (COAST). NCT04757636, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04757636 (2022, accessed 8 October 2022)."},{"key":"bibr33-20406223221140395","unstructured":"Opthea Limited. OPT-302 with ranibizumab in neovascular age-related macular degeneration (nAMD) (ShORe). NCT04757610, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04757610 (2022, accessed 8 October 2022)."},{"key":"bibr34-20406223221140395","unstructured":"PanOptica I. Study of PAN-90806 eye drops, suspension for neovascular AMD \u2013 full text view. ClinicalTrials.gov, NCT03479372, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03479372?term=pan-90806&phase=12&draw=2&rank=1 (accessed 8 October 2022)."},{"key":"bibr35-20406223221140395","unstructured":"Graybug Vision. A depot formulation of sunitinib malate (GB-102) compared to aflibercept in subjects with wet AMD \u2013 full text view. ClinicalTrials.gov, NCT03953079, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03953079?term=gb-102&phase=1&draw=2&rank=2 (accessed 8 October 2022)."},{"key":"bibr36-20406223221140395","unstructured":"Graybug Vision. A depot formulation of sunitinib malate (GB-102) in subjects with diabetic macular edema and retinal vein occlusion \u2013 full text view. ClinicalTrials.gov, NCT04085341, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04085341?term=gb-102&phase=1&draw=2&rank=1 (accessed 8 October 2022)."},{"key":"bibr37-20406223221140395","doi-asserted-by":"publisher","DOI":"10.1097\/APO.0000000000000291"},{"key":"bibr38-20406223221140395","unstructured":"Ocular Therapeutix I. Study evaluating the treatment of OTX-TKI for subjects with neovascular age-related macular degeneration \u2013 full text view. ClinicalTrials.gov, NCT04989699, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04989699?term=otx-tki&phase=01&draw=2&rank=1 (accessed 8 October 2022)."},{"key":"bibr39-20406223221140395","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.03.023"},{"key":"bibr40-20406223221140395","doi-asserted-by":"publisher","DOI":"10.3390\/cells9081869"},{"key":"bibr41-20406223221140395","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2019.1636031"},{"key":"bibr42-20406223221140395","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100906"},{"key":"bibr43-20406223221140395","doi-asserted-by":"publisher","DOI":"10.1177\/25158414211027708"},{"key":"bibr44-20406223221140395","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-020-00221-4"},{"key":"bibr45-20406223221140395","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.723"},{"key":"bibr46-20406223221140395","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2019.04.029"},{"key":"bibr47-20406223221140395","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2018.01.008"},{"key":"bibr48-20406223221140395","first-page":"7301","volume":"63","author":"Beebe JS","year":"2003","journal-title":"Cancer Res"},{"key":"bibr49-20406223221140395","first-page":"93","volume":"5","author":"Stewart M.","year":"2017","journal-title":"Eur Med J"},{"key":"bibr50-20406223221140395","unstructured":"Bingaman DP, Chaney PG, Wax MB. Ocular formulations for drug-delivery and protection of the anterior segment of the eye. Patent application US2019314343A1, USA, 2019."},{"key":"bibr51-20406223221140395","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-020-0770-y"},{"key":"bibr52-20406223221140395","first-page":"218","volume":"62","author":"Wong JG","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bibr53-20406223221140395","first-page":"1","volume":"2","author":"Yerramothu P.","year":"2018","journal-title":"Vis"},{"key":"bibr54-20406223221140395","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19124034"},{"key":"bibr55-20406223221140395","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/783163"},{"key":"bibr56-20406223221140395","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.2147\/DDDT.S115121","volume":"10","author":"Yang S","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"bibr57-20406223221140395","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.61.10.35"},{"key":"bibr58-20406223221140395","doi-asserted-by":"publisher","DOI":"10.1179\/135100003225002673"},{"key":"bibr59-20406223221140395","unstructured":"Allegro Ophthalmics L. Phase 2 randomized clinical trial of Luminate\u00ae as compared to Avastin\u00ae in the treatment of diabetic macular edema \u2013 full text view. ClinicalTrials.gov, NCT02348918, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02348918?term=luminate&phase=12&draw=2&rank=3 (accessed 9 October 2022)."},{"key":"bibr60-20406223221140395","doi-asserted-by":"publisher","DOI":"10.3390\/antib7010008"},{"key":"bibr61-20406223221140395","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0438014100"},{"key":"bibr62-20406223221140395","first-page":"4434","volume":"57","author":"JCN","year":"2016","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"bibr63-20406223221140395","unstructured":"Iconic Therapeutics I. Study evaluating intravitreal hI-con1TM in patients with choroidal neovascularization secondary to age-related macular degeneration \u2013 full text view. ClinicalTrials.gov, NCT02358889, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02358889?term=icon-1&phase=12&draw=2&rank=2 (accessed 9 October 2022)."},{"key":"bibr64-20406223221140395","doi-asserted-by":"publisher","DOI":"10.2174\/1568010033344480"},{"key":"bibr65-20406223221140395","doi-asserted-by":"publisher","DOI":"10.1038\/nature08151"},{"key":"bibr66-20406223221140395","unstructured":"Alkahest I. Evaluate the therapeutic effects and safety of ALK4290 in patients with refractory wet age-related macular degeneration \u2013 full text view. ClinicalTrials.gov, NCT03558074, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03558074?term=AKST4290&phase=12&draw=2&rank=5 (accessed 9 October 2022)."},{"key":"bibr67-20406223221140395","unstructured":"Alkahest I. A study to assess the efficacy and safety of AKST4290 with aflibercept in patients with newly diagnosed nAMD \u2013 full text view. ClinicalTrials.gov, NCT04331730, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04331730?term=AKST4290&phase=12&draw=2&rank=4 (accessed 9 October 2022)."},{"key":"bibr68-20406223221140395","unstructured":"Glendenning A, Crews KM, Sturdivant JM, et al. Sustained release, biodegradable PEA implants for intravitreal delivery of the ROCK\/PKC inhibitor AR-13503, https:\/\/iovs.arvojournals.org\/article.aspx?articleid=2692993 (2018, accessed 21 October 2020)."},{"key":"bibr69-20406223221140395","first-page":"5387","volume":"60","author":"Ding J","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bibr70-20406223221140395","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.01.040"},{"key":"bibr71-20406223221140395","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2015.09.004"},{"key":"bibr72-20406223221140395","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-017-0536-9"},{"key":"bibr73-20406223221140395","unstructured":"InflammX. XiflamTM. InflammX Therapeutics, Inc, https:\/\/inflammx.com\/xiflam (accessed 9 October 2022)."},{"key":"bibr74-20406223221140395","doi-asserted-by":"publisher","DOI":"10.1038\/mtm.2016.34"},{"key":"bibr75-20406223221140395","first-page":"105","volume":"9","author":"Herzog RW","year":"2010","journal-title":"Discov Med"},{"key":"bibr76-20406223221140395","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2019.00868"},{"key":"bibr77-20406223221140395","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2019.05.038"},{"key":"bibr78-20406223221140395","first-page":"1422","volume":"59","author":"Ammar MJ","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bibr79-20406223221140395","first-page":"1497","volume":"63","author":"Khanani AM.","year":"2022","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bibr80-20406223221140395","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2020.06.007"},{"key":"bibr81-20406223221140395","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.11.003"},{"key":"bibr82-20406223221140395","first-page":"1154","volume":"61","author":"Khanani AM","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bibr83-20406223221140395","first-page":"5","volume":"8","author":"Sabbagh O","year":"2020","journal-title":"Retin Spec"},{"key":"bibr84-20406223221140395","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2019.05.006"},{"key":"bibr85-20406223221140395","unstructured":"Janssen Research Development LLC. AAVCAGsCD59 for the treatment of wet AMD \u2013 full text view. ClinicalTrials.gov, NCT03585556, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03585556?term=hmr59&phase=012&draw=2&rank=3 (accessed 9 October 2022)."},{"key":"bibr86-20406223221140395","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2016.117"}],"container-title":["Therapeutic Advances in Chronic Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406223221140395","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20406223221140395","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406223221140395","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:19:22Z","timestamp":1777591162000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20406223221140395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":86,"alternative-id":["10.1177\/20406223221140395"],"URL":"https:\/\/doi.org\/10.1177\/20406223221140395","relation":{},"ISSN":["2040-6223","2040-6231"],"issn-type":[{"value":"2040-6223","type":"print"},{"value":"2040-6231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]},"article-number":"20406223221140395"}}